Stock Groups

Novartis buys gene therapy company Arctos Medical By Reuters


© Reuters.

ZURICH, (Reuters) – Novartis bought Arctos Medical, a gene therapy company that specialises in treating patients suffering from severe vision impairments. The Swiss firm announced Tuesday.

Novartis said the purchase, which was for an undisclosed price, demonstrates their commitment to optogenetics-based therapies that can restore vision to those with advanced blindness.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are provided by market makers. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.